Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Shinji Itoh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0382-2520; OpenAlex author ID A5045293577. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 4 papers · 2024: 1 paper

Papers 14

  1. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  2. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoper… First author DOI 10.1007/s10147-023-02399-7↗
  3. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  4. Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348221086782↗
  5. Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer. Co-author DOI 10.1177/00031348221117034↗
  6. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Co-author DOI 10.1016/j.pan.2021.08.003↗
  7. Impact of Capicua on Pancreatic Cancer Progression. First author DOI 10.1245/s10434-020-09339-z↗
  8. ASO Author Reflections: A New Prognostic Factor for Pancreatic Cancer. First author DOI 10.1245/s10434-020-09386-6↗
  9. Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04324-8↗
  10. Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.07.011↗
  11. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2019.02.038↗
  12. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Co-author DOI 10.1002/cam4.1087↗
  13. Surgical Results of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: a Multi-institutional Retrospective Study of 174 patients. Co-author PMID 27127150↗
  14. Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced panc… Co-author PMID 25964569↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tomoharu Yoshizumi · 10 shared papers, 2015–2023 · strength 1.01
  2. Masaki Mori · 5 shared papers, 2020–2021 · strength 0.61
  3. Tomohiro Iguchi · 4 shared papers, 2020–2023 · strength 0.57
  4. Keishi Sugimachi · 5 shared papers, 2016–2023 · strength 0.56
  5. Shohei Yoshiya · 4 shared papers, 2020–2021 · strength 0.50
  6. Toru Ikegami · 5 shared papers, 2016–2020 · strength 0.40
  7. Norifumi Iseda · 2 shared papers, 2023 · strength 0.38
  8. Hiroshi Matsuura · 2 shared papers, 2023 · strength 0.38
  9. Yoshinao Oda · 4 shared papers, 2017–2021 · strength 0.37
  10. Kentaro Sudo · 2 shared papers, 2023–2024 · strength 0.28
  11. Nobuhisa Matsuhashi · 2 shared papers, 2023–2024 · strength 0.28
  12. Kumiko Umemoto · 2 shared papers, 2023–2024 · strength 0.28
  13. Nobumasa Mizuno · 2 shared papers, 2023–2024 · strength 0.28
  14. Masayuki Furukawa · 2 shared papers, 2023–2024 · strength 0.28
  15. Masafumi Ikeda · 2 shared papers, 2023–2024 · strength 0.28
  16. Naohiro Okano · 2 shared papers, 2023–2024 · strength 0.28
  17. Koushiro Ohtsubo · 2 shared papers, 2023–2024 · strength 0.28
  18. Yasuyuki Kawamoto · 2 shared papers, 2023–2024 · strength 0.28
  19. Makoto Ueno · 2 shared papers, 2023–2024 · strength 0.28
  20. Chigusa Morizane · 2 shared papers, 2023–2024 · strength 0.28
  21. Yoshihiko Maehara · 4 shared papers, 2015–2019 · strength 0.25
  22. Tohru Utsunomiya · 2 shared papers, 2021–2023 · strength 0.25
  23. Kyohei Yugawa · 2 shared papers, 2020–2021 · strength 0.21
  24. Hideo Baba · 2 shared papers, 2015–2023 · strength 0.19
  25. Shoichi Inokuchi · 2 shared papers, 2020 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.